Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Double-blind, Randomised, Placebo-controlled Study Investigating the Efficacy and Safety of NTI164 in Children and Young Adults With Autism Spectrum Disorder

NCT07257939 is registered in ClinicalTrials.gov with Fenix Innovation Group as lead sponsor.

NCT NCT07257939
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07257939 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Double-blind, Randomised, Placebo-controlled Study Investigating the Efficacy and Safety of NTI164 in Children and Young Adults With Autism Spectrum Disorder
Lead sponsor
Fenix Innovation Group
Phase
Phase 3
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
July 1, 2030
Enrollment
200 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

autism, autism disorder, autism spectrum disorder